GO:0050892 intestinal absorption: Nutrient Uptake Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050892 intestinal absorption is defined as the biological process in which nutrients are taken up from the contents of the intestine.
• This process is essential for energy balance, growth, and whole-body nutrient homeostasis, and its dysfunction contributes to malabsorption, obesity, and cardiovascular disease.
• Intestinal absorption encompasses multiple routes including transcellular transport, paracellular diffusion, and carrier-mediated uptake of fats, sterols, and macromolecules.
• Key genes and proteins involved include NPC1L1, ABCG5/ABCG8, CD36, FABP2, SLC15A1, and SLC5A1, which mediate cholesterol, fatty acid, peptide, and glucose uptake.
• Absorption is regulated by hemodynamics, intestinal motility, and dietary factors, and can be enhanced or inhibited pharmacologically.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of intestinal absorption genes in vitro and in vivo.
Description
Intestinal absorption (GO:0050892) is the biological process by which nutrients are taken up from the contents of the intestine into the body. This process is fundamental for providing energy, essential lipids, amino acids, vitamins, and minerals to all tissues, and it determines the bioavailability of dietary components and orally administered drugs. The intestinal epithelium is a highly specialized barrier that coordinates digestion, transport, and metabolism, and its absorptive functions are critical for systemic homeostasis. Defects in intestinal absorption lead to malabsorption syndromes, while excessive absorption of cholesterol and fatty acids contributes to atherosclerosis, obesity, and metabolic disease. Consequently, understanding the molecular mechanisms, genetic determinants, and regulatory pathways of intestinal absorption is a major focus in gastroenterology, nutrition, and drug delivery research. This article provides a research-grade overview of GO:0050892, integrating authoritative ontology data with published literature to support experimental design and therapeutic development.
intestinal absorption At A Glance
| GO ID | GO:0050892 |
|---|---|
| GO term | intestinal absorption |
| Ontology | biological_process |
| Synonym | none |
| Definition | A process in which nutrients are taken up from the contents of the intestine. |
| Major function | Uptake of dietary nutrients, sterols, fats, peptides, and macromolecules across the intestinal epithelium. |
| Related processes | Lipid absorption, cholesterol absorption, drug absorption, macromolecule uptake. |
| Key transport routes | Transcellular, paracellular, carrier-mediated, endocytic. |
| Physiological context | Small intestine (jejunum, ileum), enterocytes, brush border membrane. |
What Is GO:0050892?
GO:0050892 intestinal absorption is defined by the Gene Ontology as a process in which nutrients are taken up from the contents of the intestine. This encompasses the transport of dietary fats, sterols, carbohydrates, amino acids, peptides, vitamins, and minerals across the intestinal epithelium, as well as the uptake of macromolecules and small particles. The process includes multiple mechanisms such as passive diffusion, facilitated transport, active carrier-mediated uptake, and endocytosis, and it is influenced by intestinal blood flow, motility, and the physicochemical properties of the lumen contents.
Why Is intestinal absorption Important in Cell Biology?
Intestinal absorption is a central physiological process that determines nutritional status, energy balance, and the bioavailability of orally administered drugs. It is directly implicated in common metabolic disorders such as hypercholesterolemia and obesity, where increased absorption of cholesterol and fatty acids drives disease progression. Moreover, understanding the mechanisms of intestinal absorption is essential for developing strategies to enhance drug uptake, treat malabsorption syndromes, and modulate nutrient sensing.
• Regulates systemic cholesterol levels and cardiovascular disease risk through intestinal sterol uptake.
• Controls dietary fat absorption, contributing to obesity and metabolic syndrome.
• Determines the oral bioavailability of drugs and xenobiotics.
• Mediates uptake of macromolecules and particles with implications for antigen sampling and drug delivery.
• Influenced by intestinal hemodynamics and blood flow, linking absorption to cardiovascular physiology.
• Can be inhibited or enhanced pharmacologically, offering therapeutic targets for malabsorption or hyperabsorption.
• Essential for mineral and trace element uptake, such as chromium absorption.
• Provides a model for studying epithelial transport and membrane biology.
• Dysregulation contributes to malnutrition, diarrhea, and inflammatory bowel disease.
• Serves as a key process for CRISPR-based functional genomics of nutrient transporters.
What Happens During intestinal absorption?
Luminal digestion and micelle formation
In simple terms: Fats and other nutrients are first broken down and packaged into tiny carriers in the gut.
Dietary fats are emulsified by bile salts and hydrolyzed by pancreatic lipases to form mixed micelles, which are essential for efficient intestinal absorption. This step increases the solubility of hydrophobic nutrients and facilitates their diffusion to the brush border membrane of enterocytes.
Brush border membrane transport
In simple terms: Nutrients cross the surface of intestinal cells through specialized transporter proteins.
The apical brush border membrane of enterocytes expresses a range of transporters and receptors that mediate nutrient uptake. For example, cholesterol absorption is facilitated by NPC1L1, while fatty acid uptake involves CD36 and FABP2. Peptide and amino acid uptake is mediated by SLC15A1 and other carriers, and glucose uptake by SLC5A1.
Intracellular processing and chylomicron assembly
In simple terms: Once inside the cell, nutrients are processed and packaged for transport into the body.
Absorbed fatty acids and cholesterol are re-esterified in the endoplasmic reticulum and assembled into chylomicrons, which are secreted into the lymph. This intracellular processing is critical for the efficient absorption of dietary fats and fat-soluble vitamins.
Basolateral export and systemic distribution
In simple terms: Packaged nutrients leave the intestinal cell and enter the bloodstream or lymph.
Chylomicrons are secreted across the basolateral membrane into the lymphatic system, eventually reaching the bloodstream. For water-soluble nutrients, basolateral transporters export them into the portal circulation. This step ensures systemic delivery of absorbed nutrients.
Paracellular and macromolecular uptake
In simple terms: Some substances pass between cells or are engulfed by cells.
In addition to transcellular transport, intestinal absorption can occur via the paracellular route, especially for small ions and water. Macromolecules and small particles can be taken up by endocytosis, a process relevant for antigen sampling and drug delivery.
Regulation by hemodynamics and motility
In simple terms: Blood flow and gut movement affect how quickly nutrients are absorbed.
Intestinal absorption is modulated by hemodynamic factors, including blood flow, which affects the removal of absorbed nutrients from the interstitial space. Intestinal motility influences transit time and thus the duration available for absorption. Pharmacological agents can enhance or inhibit absorption by altering these parameters.
Key Genes Involved in GO:0050892 intestinal absorption
The following genes and proteins are central to intestinal absorption, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NPC1L1 | Cholesterol uptake transporter | Target for cholesterol absorption inhibitors; KO models reduce cholesterol absorption |
| ABCG5 | Sterol efflux pump | Limits intestinal sterol absorption; mutations cause sitosterolemia |
| ABCG8 | Sterol efflux pump | Heterodimerizes with ABCG5; regulates plant sterol absorption |
| CD36 | Fatty acid translocase | Mediates long-chain fatty acid uptake; KO alters fat absorption |
| FABP2 | Intestinal fatty acid-binding protein | Intracellular trafficking of fatty acids; polymorphisms linked to metabolic traits |
| SLC15A1 | Peptide transporter 1 (PEPT1) | Dipeptide and peptide uptake; drug absorption target |
| SLC5A1 | Sodium-glucose cotransporter 1 (SGLT1) | Glucose and galactose uptake; mutations cause glucose-galactose malabsorption |
| SLC6A19 | Neutral amino acid transporter | Amino acid absorption; mutations cause Hartnup disorder |
| APOA4 | Apolipoprotein A-IV | Chylomicron assembly and lipid absorption |
| MTTP | Microsomal triglyceride transfer protein | Lipid transfer for chylomicron assembly; mutations cause abetalipoproteinemia |
| SAR1B | GTPase involved in COPII vesicle formation | Chylomicron secretion; mutations cause chylomicron retention disease |
| CUBN | Cubilin receptor | Vitamin B12 and protein uptake; mutations cause megaloblastic anemia |
| AMN | Amnionless | Cubilin complex for B12 absorption; mutations cause Imerslund-Gräsbeck syndrome |
| TF | Transferrin | Iron absorption and transport |
| SLC11A2 | Divalent metal transporter 1 (DMT1) | Iron and metal ion uptake |
| SLC30A10 | Manganese efflux transporter | Manganese homeostasis; mutations cause hypermanganesemia |
| CLDN2 | Claudin-2 | Paracellular permeability; regulates ion and water absorption |
| CLDN15 | Claudin-15 | Paracellular cation selectivity; KO affects absorption |
How Is intestinal absorption Regulated?
Intestinal absorption is regulated at multiple levels. Hemodynamic factors such as intestinal blood flow influence the rate of nutrient removal from the interstitium, thereby affecting net absorption. Intestinal motility modulates transit time and contact of luminal contents with the epithelium. Pharmacological agents can enhance absorption by altering mucosal permeability, transporter activity, or transit time. Additionally, dietary composition and bile salt secretion regulate lipid absorption. At the molecular level, expression of transporters such as NPC1L1 and CD36 is subject to transcriptional and post-transcriptional control, though specific pathways are beyond the scope of this article.
intestinal absorption and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NPC1L1 | Hypercholesterolemia, cholesterol absorption | KO and overexpression in Caco-2 cells; mouse KO |
| ABCG5/ABCG8 | Sitosterolemia, plant sterol accumulation | Knock-in of patient mutations in cell lines |
| SLC5A1 | Glucose-galactose malabsorption | Point mutation knock-in in intestinal organoids |
| CUBN/AMN | Imerslund-Gräsbeck syndrome (B12 malabsorption) | KO in HEK293 or intestinal epithelial cells |
| CD36 | Fatty acid absorption, obesity | KO and tagged knock-in in mouse models |
Malabsorption syndromes
Defects in intestinal absorption cause malabsorption syndromes characterized by nutrient deficiencies, diarrhea, and weight loss. For example, mutations in SLC5A1 cause glucose-galactose malabsorption, and mutations in SLC6A19 cause Hartnup disorder. Impaired vitamin B12 uptake due to CUBN or AMN mutations leads to megaloblastic anemia.
Cardiovascular and metabolic disease
Excessive intestinal absorption of cholesterol and fatty acids contributes to hypercholesterolemia, atherosclerosis, and obesity. NPC1L1 and ABCG5/ABCG8 are key determinants of cholesterol absorption and are targets for therapeutic intervention. CD36 and FABP2 variants have been associated with metabolic traits.
Drug bioavailability and toxicity
Intestinal absorption determines the oral bioavailability of drugs and xenobiotics. Transporters such as SLC15A1 and SLC5A1 mediate uptake of peptide-like drugs and glucose analogs, respectively. Modulation of absorption is a strategy for enhancing drug delivery or reducing toxicity.
From intestinal absorption-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X mediate cholesterol uptake? | CRISPR KO in Caco-2 cells; cholesterol absorption assay |
| Does mutation Y affect transporter function? | Point mutation knock-in in intestinal organoids |
| Where is protein Z localized in enterocytes? | Tagged knock-in (e.g., GFP) in cell lines |
| Does overexpression of gene W enhance absorption? | Overexpression in Caco-2 or IEC-6 cells |
| What is the role of gene V in vivo? | Mouse KO or conditional KO |
| Can CRISPR screen identify novel absorption regulators? | Genome-wide CRISPR library screening in intestinal cells |
How to Study the intestinal absorption Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Caco-2 transport assay | Apical-to-basolateral flux | Drug and nutrient absorption screening |
| Cholesterol absorption assay | Fractional cholesterol absorption | NPC1L1 and ABCG5/G8 function |
| Lymph fistula | Chylomicron secretion | In vivo fat absorption |
| CRISPR KO | Gene function loss | Identify essential transporters |
| CRISPR knock-in | Mutant protein function | Model patient mutations |
| Organoid culture | Epithelial transport | Human-relevant absorption studies |
| RNA-seq | Transcriptional changes | Pathway analysis after manipulation |
| Proteomics | Protein abundance and interactions | Transporter complexes |
In vitro absorption assays
Caco-2 cell monolayers and intestinal organoids are widely used to measure nutrient and drug transport across the intestinal epithelium. These models allow quantification of apical-to-basolateral flux and the effects of genetic manipulation.
Genetic manipulation with CRISPR
CRISPR-Cas9 knockout, point mutation knock-in, and overexpression are used to dissect the function of absorption-related genes in cell lines and organoids. These approaches enable causal testing of candidate transporters and regulators.
In vivo absorption studies
Mouse models with intestinal-specific knockout or knock-in of absorption genes allow measurement of lipid, sterol, and drug absorption in vivo. Lymph fistula and dual-isotope methods are used to quantify absorption.
Omics and imaging
RNA-seq, proteomics, and lipidomics can profile changes in transporter expression and lipid species after genetic manipulation. Imaging of fluorescently tagged transporters provides spatial information in enterocytes.
How CRISPR Can Be Used to Study GO:0050892 intestinal absorption
Knockout
CRISPR knockout of absorption-related genes such as NPC1L1 or CD36 in Caco-2 cells or mouse models abolishes or reduces nutrient uptake, providing causal evidence for their role. Knockout models are essential for validating candidate transporters identified in screens.
Point Mutation
Point mutation knock-in can model human polymorphisms or disease-causing variants in transporters like SLC5A1 or ABCG5/ABCG8, allowing functional assessment of specific amino acid changes.
Knock-in
Tagged knock-in (e.g., GFP or HA) enables visualization and immunoprecipitation of endogenous absorption proteins, revealing localization and interaction partners in enterocytes.
Overexpression
Overexpression of transporters or regulatory proteins in intestinal cell lines can enhance absorption and test sufficiency. For example, overexpression of NPC1L1 increases cholesterol uptake.
How EDITGENE Supports intestinal absorption Research
Researchers studying intestinal absorption-related genes often need to determine whether a candidate gene is causally involved in nutrient uptake, and CRISPR-based models provide the most direct approach. EDITGENE offers a comprehensive suite of services to support functional genomics of GO:0050892.
Contact EDITGENE today to design your custom CRISPR model for intestinal absorption research.
Frequently Asked Questions About intestinal absorption
What is GO:0050892 intestinal absorption?
GO:0050892 is a Gene Ontology biological process term defined as the process in which nutrients are taken up from the contents of the intestine.
What genes are involved in intestinal absorption?
Key genes include NPC1L1, ABCG5, ABCG8, CD36, FABP2, SLC15A1, SLC5A1, and CUBN, among others.
How is intestinal absorption regulated?
It is regulated by hemodynamics, intestinal motility, dietary factors, and pharmacological agents that alter transporter activity or permeability.
What diseases are associated with defective intestinal absorption?
Malabsorption syndromes, glucose-galactose malabsorption, Hartnup disorder, sitosterolemia, and Imerslund-Gräsbeck syndrome.
How can CRISPR be used to study intestinal absorption?
CRISPR knockout, knock-in, and overexpression in intestinal cell lines and organoids enable causal testing of candidate genes.
What models are used to study intestinal absorption?
Caco-2 cells, intestinal organoids, and mouse models are commonly used.
What is the role of NPC1L1 in cholesterol absorption?
NPC1L1 is a key transporter mediating intestinal cholesterol uptake and is the target of ezetimibe.
How does CD36 contribute to fat absorption?
CD36 facilitates fatty acid uptake across the brush border membrane of enterocytes.
What is the paracellular route of intestinal absorption?
It is the passage of substances between epithelial cells, regulated by tight junction proteins like claudins.
Can intestinal absorption be enhanced for drug delivery?
Yes, absorption enhancers can increase drug uptake by modulating permeability or transporter activity.
Conclusion
GO:0050892 intestinal absorption is a fundamental biological process that governs nutrient uptake and systemic homeostasis. Its dysregulation underlies major metabolic and gastrointestinal diseases, and it is a key determinant of drug bioavailability. Advances in CRISPR-based models and functional genomics are accelerating the discovery of new transporters and regulatory mechanisms, offering opportunities for therapeutic intervention in malabsorption and cardiometabolic disorders.
References
- 1. Dawson PA et al.. 1999. Intestinal cholesterol absorption.. Curr Opin Lipidol 10(4):315-20 PMID: 10482134
- 2. SENIOR JR. 1964. INTESTINAL ABSORPTION OF FATS.. J Lipid Res 5:495-521 PMID: 14221094
- 3. Unknown. 1967. Intestinal absorption of chromium.. Nutr Rev 25(3):76-8 PMID: 5343320
- 4. Unknown. 1967. Intestinal absorption.. Br Med J 4(5578):503-4 PMID: 6065980
- 5. Sanford PA. 1967. Inhibition of intestinal absorption.. Br Med Bull 23(3):270-4 PMID: 4864375
- 6. Mailman D. 1982. Relationships between intestinal absorption and hemodynamics.. Annu Rev Physiol 44:43-55 PMID: 6122423
- 7. Seifert J et al.. 1990. Intestinal absorption of macromolecules and small particles.. Dig Dis 8(3):169-78 PMID: 2186882
- 8. van Hoogdalem EJ et al.. 1989. Intestinal drug absorption enhancement: an overview.. Pharmacol Ther 44(3):407-43 PMID: 2519349
